Is Combination Sulfonylurea and Insulin Therapy Useful in NIDDM Patients?: A metaanalysis
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To assess the efficacy of combination therapy with insulin and sulfonylurea in the treatment of NIDDM. RESEARCH DESIGN AND METHODS: Studies published between January 1966 and January 1991 were identified through a computerized Medline search and by hand searching the bibliographies of identified articles. We identified 17 eligible randomized, controlled trials of combination therapy in NIDDM. These trials had a minimum duration of 8 wk and at least one of three outcome measures (fasting glucose, HbA1, or C-peptide) with SD or SE of the mean reported to do metaanalysis. With standardized forms, three independent reviews abstracted measures of study quality and specific descriptive information about population, intervention, and outcome measurements. RESULTS: We calculated effect size and weighted mean changes of the three outcome measures for control and treatment groups. In the treatment group, the fasting plasma glucose decreased from a mean of 11.4 mM (206 mg/dl) at baseline to a mean of 9.16 mM (165 mg/dl) posttreatment, whereas the control group decreased from (11.3 to 10.8 mM) (204 to 194 mg/dl) (effect size 0.39, P < 0.0001). For HbA1, the treatment group decreased from a baseline of 11.0 to 10.2% compared to 11.0 and 11.2% in the control group (effect size 0.43, P < 0.0001). For fasting C-peptide, the treatment group increased from 0.49 to 0.58 nM (1.45 to 1.75 ng/ml) compared with 0.47 and 0.43 (1.42 and 1.30) for the control group (effect size 0.26, P < 0.017). CONCLUSION: Combined insulin-sulfonylurea therapy leads to modest improvement in glycemic control compared with insulin therapy alone. With combined therapy, lower insulin doses may be used to achieve similar control. Obese patients with higher fasting C-peptides may be more likely to respond than others.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Fail-Safe N for Effect Size in Meta-Analysis
Orwin, R. G. (1983) · Journal of Educational Statistics · doi:10.2307/1164923 · Cited by 2,064 · cited 1×
“To determine the number of trials that would be needed to overturn or disprove the results, we calculated a "fail-safe N" with the method of Orwin (12).”
Method
Cited by
Yki-Järvinen, H., Dressler, A., Ziemen, M., & HOE 901/300s Study Group (2000) · Diabetes Care · doi:10.2337/diacare.23.8.1130 · Cited by 579
Insulin glargine or NPH combined with metformin in type 2 diabetes: The LANMET study
Yki-Järvinen, H., Kauppinen-Mäkelin, R., Tiikkainen, M., Vähätalo, M., Virtamo, H., Nikkilä, K., Tulokas, T., Hulme, S., Hardy, K., McNulty, S., et al. (2006) · Diabetologia · doi:10.1007/s00125-005-0132-0 · Cited by 434
Yki-Järvinen, H., Ryysy, L., Nikkilä, K., Tulokas, T., Vanamo, R., & Heikkilä, M. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-5-199903020-00002 · Cited by 433
“On the basis of analysis of predictors of treatment responses in previous studies (3, 7, 13) and data from monotherapy trials of metformin (14, 15), we hypothesized that self-adjustment of the insulin dose and use of metformin in addition to insulin might offer therapeutic benefits.”
BackgroundCombination therapies with insulin in type 2 diabetes
Yki-Järvinen, H. (2001) · Diabetes Care · doi:10.2337/diacare.24.4.758 · Cited by 300
“These studies are the focus of this review and include studies comparing insulin alone to combination therapy with insulin and sulfonylureas (subject to meta-analyses in 1991 and 1992) (4,5) and more recent trials using metformin, glitazones, or acarbose in insulin combination therapy regimens.”
Estimating the effect of sulfonylurea on HbA1c in diabetes: a systematic review and meta-analysis
Hirst, J. A., Farmer, A. J., Dyar, A., Lung, T. W. C., & Stevens, R. J. (2013) · Diabetologia · doi:10.1007/s00125-013-2856-6 · Cited by 173
“6% or 7 mmol/mol lower), than insulin treatment alone and resulted in use of a lower insulin dose for these patients, consistent with other reports [9].”
Metadata
- Authors
- Pugh, J. A., Wagner, M. L., Sawyer, J., Ramirez, G., Tuley, M., & Friedberg, S. J.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 1992-08-01
- Volume
- 15
- Issue
- 8
- Pages
- 953-959
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W1978205142
- Cited by
- 105
- References
- 1
- FWCI
- 2.48
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Is Combination Sulfonylurea and Insulin Therapy Useful in NIDDM Patients?: A metaanalysis. https://app.cochat.ai/papers/10.2337/diacare.15.8.953
- The paper
- Pugh, J. A., Wagner, M. L., Sawyer, J., Ramirez, G., Tuley, M., & Friedberg, S. J. (1992). Is Combination Sulfonylurea and Insulin Therapy Useful in NIDDM Patients?: A metaanalysis. Diabetes Care. https://doi.org/10.2337/diacare.15.8.953
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.